Effect of human seminal plasma on tumour-associated immunity in prostatic cancer. A preliminary report.
Evidence of significant suppression of tumour-associated immunity in patients with prostatic cancer by human seminal plasma (HuSPl) has been observed. Collation of the immunosuppressive property of HuSPl in this and previous studies, together with recent studies demonstrating experimental induction of prostatic cancer by spermatozoa and the relationship of prostatic cancer to sexual activity are suggestive of an etiologic role for SPl in prostatic cancer.